{"title":"Chapter 5: Advanced HIV disease","nid":651,"vid":2861,"created":1636998368,"changed":1637046329,"field_accordian_header":[{"field_accordian":[{"field_title":"5.3 Providing a package of care","field_content":"<p>A package of interventions including screening, treatment and\/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>\r\n","field_icon":null},{"field_title":"5.4 Overview of clinical management of cryptococcal disease","field_content":"<p>A package of interventions including screening, treatment and\/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease (strong recommendation, moderate-certainty evidence).<\/p>\r\n\r\n<p><strong>Diagnosis of cryptococcal meningitis<\/strong><\/p>\r\n\r\n<p>For adults, adolescents and children living with HIV suspected of having a first episode of cryptococcal meningitis, prompt lumbar puncture with measurement of CSF opening pressure and rapid cryptococcal antigen assay is recommended as the preferred diagnostic approach <em>(strong recommendation, moderate-certainty evidence for adults and adolescents).<\/em><\/p>\r\n\r\n<p>The following diagnostic approaches are recommended, according to the context:<\/p>\r\n\r\n<p><strong>Settings with ready access to and no contraindication for lumbar puncture<\/strong><\/p>\r\n\r\n<ol>\r\n\t<li>If both access to a cryptococcal antigen assay (either lateral flow assay or latex agglutination assay) and rapid results (less than 24 hours) are available: lumbar puncture with rapid CSF cryptococcal antigen assay is the preferred diagnostic approach <em>(strong recommendation, moderate-certainty evidence for adults and adolescents).<\/em><\/li>\r\n\t<li>If access to a cryptococcal antigen assay is not available and\/or rapid results are not available: lumbar puncture with CSF India ink test examination is the preferred diagnostic approach <em>(strong recommendation, moderate-certainty evidence for adults and adolescents).<\/em><\/li>\r\n<\/ol>\r\n\r\n<p><strong>Settings without immediate access to lumbar puncture or when lumbar puncture is clinically contraindicated such as significant coagulopathy or suspected space-occupying lesion based on focal nervous system signs or recurrent seizures<\/strong><\/p>\r\n\r\n<ol>\r\n\t<li>If both access to a cryptococcal antigen assay and rapid results (less than 24 hours) are available: rapid serum, plasma or whole-blood cryptococcal antigen assays are the preferred diagnostic approaches <em>(strong recommendation, moderate-certainty evidence for adults and adolescents).<\/em><\/li>\r\n\t<li>If a cryptococcal antigen assay is not available and\/or rapid access to results is not ensured: prompt referral for further investigation and treatment as appropriate <em>(strong recommendation, moderate-certainty evidence for adults and adolescents).<\/em><\/li>\r\n<\/ol>\r\n\r\n<p><strong>Prevention and screening<\/strong><\/p>\r\n\r\n<p>Screening for cryptococcal antigen followed by pre-emptive antifungal therapy among cryptococcal antigen-positive people to prevent the development of invasive cryptococcal disease are recommended before initiating or reinitiating ART for adults and adolescents living with HIV who have a CD4 count &lt;100 cells\/mm\u00b3 <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p>This may be considered at a higher CD4 cell count threshold of &lt;200 cells\/mm\u00b3 <em>(conditional recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p>All people living with HIV with a positive cryptococcal antigen result on screening should be carefully evaluated for signs and symptoms of meningitis and undergo a lumbar puncture, if feasible, with CSF examination and India ink or CSF cryptococcal antigen assay to exclude active cryptococcal disease. India ink has low sensitivity, and a negative result on India ink should be confirmed by CSF cryptococcal antigen testing. When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given to adults and adolescents living with HIV who have a CD4 count &lt;100 cells\/mm\u00b3 <em>(strong recommendation, moderate-certainty evidence). <\/em>This may be considered at a higher CD4 cell count threshold of &lt;200 cells\/mm\u00b3 <em>(conditional recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Treatment<\/strong><\/p>\r\n\r\n<p><strong>The following is recommended as the preferred induction regimen.<\/strong><\/p>\r\n\r\n<p>For adults, adolescents and children, a short-course (one-week) induction regimen with amphotericin B deoxycholate (1.0 mg\/kg per day) and flucytosine (100 mg\/kg per day, divided into four doses per day) is the preferred option for treating cryptococcal meningitis among people living with HIV <em>(strong recommendation, moderate-certainty evidence for adults).<\/em><\/p>\r\n\r\n<p><strong>The following induction regimens are recommended as alternative options.<\/strong><\/p>\r\n\r\n<ul>\r\n\t<li>Two weeks of fluconazole (1200 mg daily, 12 mg\/kg per day for children and adolescents) + flucytosine (100 mg\/kg per day, divided into four doses per day) <em>(strong recommendation, moderate-certainty evidence).<\/em><\/li>\r\n\t<li>Two weeks of amphotericin B deoxycholate (1.0 mg\/kg per day) + fluconazole (1200 mg daily, 12 mg\/kg per day for children and adolescents up to a maximum of 800 mg daily) <em>(strong recommendation, moderate-certainty evidence).<\/em><\/li>\r\n<\/ul>\r\n\r\n<p><strong>Consolidation<\/strong><\/p>\r\n\r\n<p>Fluconazole (400-800 mg daily for adults or 6-12 mg\/kg per day for children and adolescents up to a maximum of 800 mg daily) is recommended for the consolidation phase (for eight weeks following the induction phase) <em>(strong recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Maintenance (or secondary prophylaxis)<\/strong><\/p>\r\n\r\n<p>Fluconazole (200 mg daily for adults or 6 mg\/kg per day for adolescents and children) is recommended for the maintenance phase <em>(strong recommendation, high-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Using adjunctive systemic corticosteroids in treating cryptococcal meningitis<\/strong><\/p>\r\n\r\n<p>Routine use of adjunctive corticosteroid therapy during the induction phase is not recommended in treating adults, adolescents and children who have HIV-associated cryptococcal meningitis <em>(strong recommendation, high-certainty evidence for adults and adolescents).<\/em><\/p>\r\n\r\n<p><strong>Timing of ART<\/strong><\/p>\r\n\r\n<p>Immediate ART initiation is not recommended among adults, adolescents and children living with HIV who have cryptococcal meningitis because of the risk of increased mortality and should be deferred 4-6 weeks from the initiation of antifungal treatment <em>(strong recommendation, low-certainty evidence for adults).<\/em><\/p>\r\n","field_icon":null},{"field_title":"5.5 Overview of clinical management of histoplasmosis","field_content":"<p><strong>Diagnosis of disseminated histoplasmosis among people living with HIV<\/strong><\/p>\r\n\r\n<p>Among people living with HIV, disseminated histoplasmosis should be diagnosed by detecting circulating Histoplasma antigens <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Induction therapy<\/strong><\/p>\r\n\r\n<p>Treating people living with HIV for severe or moderately severe histoplasmosis: liposomal amphotericin B, 3.0 mg\/kg, for two weeks is recommended. In settings in which liposomal amphotericin B is unavailable, deoxycholate amphotericin B, 0.7-1.0 mg\/kg, is recommended for two weeks <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Good practice statements<\/strong><\/p>\r\n\r\n<p>As a good practice for people with renal failure, or at risk of renal injury, measures to prevent or treat toxicity are recommended.<\/p>\r\n\r\n<p>Induction therapy should be given for two weeks. Since deoxycholate amphotericin B may be associated with renal toxicity, therapy may need to be shorter than two weeks based on the clinical assessment of how the person responds to treatment. Involvement of the central nervous system may require extending induction therapy or increasing dosage.<\/p>\r\n\r\n<p>Treating people living with HIV for mild to moderate histoplasmosis: itraconazole 200 mg three times daily for three days and then 200 mg twice daily is recommended <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Maintenance therapy<\/strong><\/p>\r\n\r\n<p>Itraconazole 200 mg twice daily for 12 months is recommended <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p>Less than 12 months of therapy can be considered when the person is clinically stable, receiving ART, has suppressed viral load and the immune status has improved <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Timing of ART<\/strong><\/p>\r\n\r\n<p>ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>TB therapy for people coinfected with TB, HIV and histoplasmosis<\/strong><\/p>\r\n\r\n<p>People living with HIV who also have TB and histoplasmosis coinfection should receive TB therapy according to WHO treatment guidelines <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n","field_icon":null}],"field_header":"Advanced HIV disease"}],"field_content_type":{"tid":8,"name":"Accord","class":"accord"}}